Oncology

The recommendations were developed on the basis of the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) ranking for genomic alterations occurring in the 8 cancers responsible for the most deaths worldwide.

These study findings suggest that the response rate to immune checkpoint blockade may be dependent on the strength of immune selection occurring early in tumorigenesis.

Bristol Myers Squibb announced that their phase 3 CheckMate-649 trial demonstrated superior overall survival and profession-free survival using nivolumab plus chemotherapy to treat patients with gastric and esophageal cancers.

The FDA approved Guardant360 CDx, the first liquid biopsy companion diagnostic that also uses next-generation sequencing technology to identify patients with any solid malignant neoplasm.

The oncologist from the Morrison Cancer Center explained why he believes the general population should not receive multi-gene panel testing.

The goal of the initiative is to have cancer screenings that were made in the first half of 2020 and cancelled due to COVID-19 rescheduled to ensure patients are again receiving routine screenings.

These findings have serious implications for future cancer care and underscore the need to resume cancer care and screening.

The National Comprehensive Cancer Network published a document intended for patients to understand how CAR-T cells work and what side effects are associated with the treatment.

The director of Molecular Pathology and assistant professor of Pathology at Cedars-Sinai spoke about the use of NGS testing to match patients with targeted therapy.

Adjuvant immunotherapy induced improved survival compared with those who did not in patients with stage 3 melanoma, according to data from a large real-world database.

RO7198457 in combination with atezolizumab induced significant levels of neoantigen-specific immune responses with a manageable safety profile in patients with locally advanced or metastatic solid tumors.

The expert from the American Cancer Society spoke about updated guidelines published recently regarding recommendations on diet and physical activity for cancer prevention.

The FDA approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high solid tumors.

Experts discuss the case of a 56-year-old white man who presents with multiple immune-related adverse events

A clinically applicable mathematical model was developed by researchers to predict outcomes to immunotherapy for patients with cancer previously treated with anti–CTLA-4 or anti–PD-1/PD-L1 antibodies.

Interim data from cohort B of KEYNOTE-555, a phase I trial evaluating a 400 mg every 6-week dosing regimen of pembrolizumab in patients with metastatic melanoma, demonstrated a consistent benefit-risk profile.

The FDA approved an additional recommended dose of 400 mg pembrolizumab (Keytruda) every 6 weeks across all adult indications.

The study found that pembrolizumab has activity in brain metastases from non-small cell lung cancer that is similar to its systemic activity and can result in prolonged survival in a subset of patients.

A recent study determined 4 distinct long noncoding RNA-based immune classes for patients with cancer and provided scores for integration into multiomic panels for precision immunotherapy.

Researchers found that the potential availability of CAR T-cell therapies for large B-cell lymphomas with lower adverse event rates that are suitable for outpatient administration may reduce the total costs of care.

The FDA cleared the investigational new drug (IND) application for the use of CYNK-001 in adults with COVID-19.

Researchers analyzed a patient population with stage IV melanoma and found no difference in the rate of surgical resection with the use of immunotherapy between the checkpoint inhibitor era and pre-checkpoint inhibitor era.

Dylan Essner discussed the implementation of documentation tools and CRS, ICANS and ICE flow sheets within CAR T-cell therapy.

The associate director for clinical research at the Washington University School of Medicine spoke about the value and challenges of using EMRs in CAR T-cell therapy.

Researchers suggested that patients with non-small cell lung cancer (NSCLC) who have higher measures of tumor mutations that appear in a blood test generally have a better clinical response to PD-1-based immunotherapy than those with a lower measure of mutations.

Karen Kelly, MD, sat down to discuss her presentation on when to start immunotherapy in a real world, patient setting.

Walter Curran, MD, detailed his presentation on immunotherapy and radiation therapy, and how integrating the 2 treatment options presents an exciting opportunity moving forward.

Gilberto Lopes, MD, MBA, FAMS, discussed his presentation about when to stop immunotherapy treatments for patients with lung cancer.

Rogerio Lilenbaum, MD, talked about the state of lung cancer in regards to immunotherapy and targeted therapy at the 17th Annual Winter Lung Conference in Miami Beach, Florida.

According to the researchers, these data suggest that checkpoint blockade in women with early-stage, high-risk, ERBB2-negative breast cancer is very likely to succeed in a phase III trial.